Last reviewed · How we verify
Lu AG22515
At a glance
| Generic name | Lu AG22515 |
|---|---|
| Also known as | APB-A1 |
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease (PHASE1)
- A Study Investigating Lu AG22515 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lu AG22515 CI brief — competitive landscape report
- Lu AG22515 updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI